U.S. FDA leaning toward approving Moderna half-dose booster – Bloomberg News

(Reuters) – The U.S. Food and Drug Administration (FDA) is leaning toward authorizing half-dose booster shots of the Moderna Inc (MRNA.O) COVID-19 vaccine, Bloomberg News reported on Tuesday, citing people familiar with the matter.

The FDA had been seeking information about the effectiveness of a full third dose of the Moderna vaccine, but is now ready to move forward and consider the half-dose booster Moderna has proposed, the report said.

Moderna and the FDA did not immediately respond to Reuters request for comment outside regular business hours.

A registered nurse applies a dose of the Moderna COVID-19 vaccine to Sarasota Hospital worker Larry Hammers, 62, at the Sarasota Memorial Hospital in Sarasota, Florida, U.S., September 24, 2021. REUTERS/Shannon Stapleton

Moderna on Sept. 1 submitted its application to the U.S. Food and Drug Administration seeking authorization for a booster shot. read more

The original Moderna vaccine contains 100-micrograms of mRNA in each shot. The company’s submission to regulators to authorize a half-dose booster would allow Moderna to produce more.

Reporting by Akriti Sharma in Bengaluru; Editing by Muralikumar Anantharaman

Our Standards: The Thomson Reuters Trust Principles.

 

Reuters source:

https://www.reuters.com/world/us/us-fda-leans-toward-nod-moderna-covid-booster-shot-half-dose-bloomberg-news-2021-09-29